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INTRODUCTION
High blood pressure (BP) is a key risk 
factor for the development of cardiovascular 
disease1 and a major cause of morbidity 
and mortality worldwide.2 An accurate BP 
monitoring device is fundamental to BP 
measurement in the diagnosis and control 
of hypertension. 
Several protocols3–5 exist for the validation 
of BP measuring devices but these are 
generally undertaken and then published on 
brand new models, and so do not guarantee 
sustained accuracy thereafter. The revised 
General Medical Services contract for UK 
GPs (2003)6 includes a recommendation 
to ensure medical equipment is regularly 
maintained, calibrated and replaced if 
necessary. Typically, new monitors are 
assumed to be accurate for 2 years and 
then annual checks are undertaken. 
However, it is not clear whether this is 
appropriate, as the drift in accuracy over 
time of an automated sphygmomanometer 
is not known. The error rate is a function 
of random (variability) and systematic 
(bias) error, and ultimately depends on the 
calibration interval of the device, and the 
conditions under which it is used.
Detection and control of hypertension 
are sub-optimal,7 and a recent study has 
identified that there are insufficient GPs in 
England to achieve high levels of detection 
while at the same time maintaining access 
to appointments with GPs.8 Community 
pharmacies are a good potential site for 
identifying cardiovascular risk factors and 
improving disease detection,9 including 
identifying people with hypertension, 
because of their accessibility and because 
many pharmacies provide free access to BP 
monitors. Pharmacists have been involved 
in successful community-based screening 
programmes developed to improve detection 
and treatment of hypertension, both in 
the UK and worldwide.10–16 Community 
pharmacy BP monitoring is readily available, 
widely demanded, and recommended by 
hypertension guidelines.11,17,18
Evidence from the US19 suggests that 
many people with hypertension check their 
BP at a pharmacy. In the UK, the ‘Know 
Your Numbers’ campaign has ensured 
that 1.5 million people have had their BP 
checked in the UK since 2001, mostly at 
community pharmacies.20
However, the few studies evaluating 
publicly available monitors have shown 
them to be inaccurate.21–27 Many of these 
studies are more than a decade old, and 
there remains limited evidence of how well 
the monitors maintain their rigour in a 
potentially challenging environment. 
Therefore, the authors assessed the 
accuracy of validated28 automatic BP 
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Abstract
Background
Free blood pressure (BP) checks offered by 
community pharmacies provide a potentially 
useful opportunity to diagnose and/or 
manage hypertension, but the accuracy of 
the sphygmomanometers in use is currently 
unknown.
Aim
To assess the accuracy of validated automatic 
BP monitors used for BP checks in a UK retail 
pharmacy chain.
Design and setting
Cross-sectional, observational study in 52 
pharmacies from one chain in a range of 
locations (inner city, suburban, and rural) in 
central England.
Method
Monitor accuracy was compared with a 
calibrated reference device (Omron PA-350), 
at 50 mmHg intervals across the range 
0–300 mmHg (static pressure test), with a 
difference from the reference monitor of +/– 
3 mmHg at any interval considered a failure. 
The results were analysed by usage rates and 
length of time in service.
Results
Of 61 BP monitors tested, eight (13%) monitors 
failed (that is, were >3 mmHg from reference), 
all of which underestimated BP. Monitor failure 
rate from the reference monitor of +/– 3 mmHg 
at any testing interval varied by length of time 
in use (2/38, 5% <18 months; 4/14, 29% >18 
months, P = 0.038) and to some extent, but 
non-significantly, by usage rates (4/22, 18% in 
monitors used more than once daily; 2/33, 6% 
in those used less frequently, P = 0.204).
Conclusion
BP monitors within a pharmacy setting fail 
at similar rates to those in general practice. 
Annual calibration checks for blood pressure 
monitors are needed, even for new monitors, as 
these data indicate declining performance from 
18 months onwards.
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monitors in a UK retail pharmacy chain, in 
which the current policy is to retire monitors 
after 2 years in service for free BP checks 
without interim calibration checks.
METHOD
The accuracy of all available digital 
sphygmomanometers (two models, both 
derived from the validated Kinetik BPM 1 
Series) in 52 pharmacies was evaluated 
through comparison to a calibrated 
reference monitor (Omron PA-350), 
at 50 mmHg intervals across the range 
0–300 mmHg, as recommended by the 
British Hypertension Society. Following 
manufacturers’ protocol, a difference from 
the reference monitor of +/– 3 mmHg at any 
interval was considered a failure. In addition 
to this static pressure test, the authors also 
conducted a visual inspection to check that 
the machine switched on and off, contained 
batteries, and had a readable display, and 
they tested deflation, air leakage, and all 
cuffs in use. Pharmacies were visited in 
a range of locations (inner city, suburban, 
and rural) in central England (Birmingham, 
Black Country, Herefordshire, and 
Worcestershire) in order to achieve a 
sample of monitors of both high and low 
use. No pharmacies refused to participate. 
All testing was undertaken by one author.
The length of time in use and number of 
recorded uses was measured in two ways:
• Pharmacy staff were asked at the time 
of the calibration visit. Very occasionally 
it was calculated by reference to a log 
book, and some monitors had stickers 
that detailed the precise date they were 
first used for BP checks, but mainly it 
was dependent on staff recall. Data on 
service duration, or length of time in use, 
were recorded only from the individual 
pharmacies. 
• Figures detailing the number of BP 
checks for each pharmacy were collected 
from the head office for the most recent 
2-year period; however, this data were 
at the pharmacy level and not available 
for individual monitors, and thus were 
of limited use in pharmacies that had 
multiple monitors. The data were also 
dependent on individual data being 
inputted every time a BP check was 
performed.
The association between monitor 
precision and both length of time in service 
and usage rate (using the data collected 
from fieldwork and those from the pharmacy 
head office, separately) was tested using 
linear regression. The linear models were 
fitted by using the mean of the differences 
as outcome, which was defined as the mean 
of the differences between the device being 
tested and the reference standard in all 
testing intervals ascending and descending. 
All model assumptions were checked. 
Failure rate by the different predictors was 
assessed using the Fisher exact test statistic.
RESULTS
Of a total of 61 monitors assessed, eight 
(13%) failed (that is, were >3 mmHg from 
reference), all of which underestimated BP. 
The largest disparity found was 8.3 mmHg 
at a pressure of 300 mmHg. The majority 
of failures were at higher pressures, and 
if a monitor failed at a given pressure it 
invariably failed at all higher pressures; 
eight failed at 300 mmHg, five failed 
from 250 mmHg, four from 200 mmHg, 
and one from 100 mmHg. At the testing 
point nearest to the diagnostic threshold 
(150 mmHg), two monitors failed (2/61, 3%).
Overall, the difference in BP between 
monitors and the reference device increased 
with level of BP in a linear fashion to a mean 
2 mmHg difference at 300 mmHg (Table 1). 
The relative difference did not appear to 
vary with pressure, as the percentage error 
was almost identical at each testing interval, 
albeit a little higher at the point closest to the 
diagnostic threshold in the testing process 
(150 mmHg), where there was a mean 
difference of just over 1 mmHg (Table 1). 
BP was underestimated in 71% of readings 
and overestimated in 22%, and the ratio of 
underestimated readings to overestimated 
readings increased with pressure: 80% 
How this fits in
The accessibility of free blood pressure 
checks provided in community pharmacies 
provides an excellent opportunity to improve 
hypertension screening and management. 
However, even when the devices have 
been clinically validated using a recognised 
protocol, there is very little evidence about 
how well they maintain their accuracy 
over time in a potentially challenging 
environment. This study therefore assessed 
the accuracy of the monitors being used 
in blood pressure checks at pharmacies; 
it is the only study the authors are aware 
of that considers the accuracy of these 
monitors, and one of the very few to assess 
accuracy of monitors with respect to time 
in service. Based on these findings, the 
authors recommend an annual calibration 
check for this type of monitor, with evidence 
suggesting performance declines from 
18 months onwards. 
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of readings were underestimated and 
16% were overestimated between 150–
250 mmHg, with 92% underestimated 
and 5% overestimated at 300 mmHg 
(Table 2). This pattern of underestimation 
is suggestive of a small systematic error 
across the monitors, but with random error 
(variability) in individual monitors.
Estimates from pharmacy staff of annual 
usage of BP monitors ranged from 104 
times to 1560 times (compounded by 
variation from the ‘Know Your Numbers’ 
campaign). The pharmacy chain’s head 
office range of estimated annual usage was 
from 14–276 times. 
Comparison of the ratio of uses between 
the two data sources was inconsistent, 
varying from a single pharmacy where 
usage data from head office was higher, to 
monitoring usage from fieldwork estimates 
being >18 times greater. In view of this, 
both estimates were used separately and 
compared in sensitivity analyses.
Length of time in service varied from 
1 week to almost 3 years, with a modal 
period of service duration of 6–12 months. 
However, there was some uncertainty about 
the time in use of several monitors, with no 
clear estimate available for nine (15%) of 
the devices.
Monitor failure rate (defined as a difference 
from the reference monitor of +/– 3 mmHg 
at any testing interval) varied by length of 
time in use (2/38, 5% <18 months compared 
with 8/61, 13% overall and versus 4/14, 29% 
>18 months, P = 0.038). To some extent 
failure rate varied by usage rates (4/22, 
18% in monitors used more than once 
daily compared with 2/33, 6% in those used 
less frequently) but this difference was not 
statistically significant (P = 0.204). A greater 
failure rate (4/13, 31%) was observed for 
higher usage when the head office data 
were used, but as this was only available at 
pharmacy level, and four failures happened 
in pharmacies where multiple devices were 
being used, the data were difficult to interpret.
The association between monitor precision 
and length of time in service (Table 3) using 
linear regression showed that the mean 
difference for monitors in service for both 
6–12 months and 13–18 months was around 
0.35 mmHg greater than that for those used 
for 0–5 months, increasing to >0.70 mmHg 
for monitors used for 19–24 months. 
However, no statistical significance could be 
observed for any of the categories.
A linear trend for predicted difference was 
found by amount of usage (for both the 
fieldwork data and that from the pharmacy’s 
head office), suggesting a drop in precision 
with high usage, but the results were not 
Table 1. Mean difference against reference standard at all testing 
intervals
 Mean difference, Error of the mean 
Pressure range, mmHg  mmHg (95% CIs) difference, %
0 0.0 (–0.01 to 0.01) —
50 0.15 (0.01 to 0.30) 0.30
100 0.42 (0.21 to 0.62) 0.42
150 1.15 (0.32 to 1.98) 0.76
200 1.14 (0.84 to 1.44) 0.57
250 1.41 (1.04 to 1.78) 0.56
300 1.90 (1.48 to 2.33) 0.63
Pressure is checked in 50 mmHg increments from 0–300 mmHg and in 50 mmHg increments down again. The 
data at each testing interval between 0–250 mmHg going up have been combined with the data going down.
Table 2. Overestimation and 
underestimation of pressure 
at all testing intervals
Pressure  Underestimate,  Overestimate,  
range, mmHg % %
0 47 32
50 58 37
100 70 25
150 78 17
200 81 17
250 82 14
300 92 5
Pressure is checked in 50 mmHg increments from 
0–300 mmHg, and in 50 mmHg increments down 
again. The data at each testing interval between 
0–250 mmHg going up have been combined with the 
data going down. Overestimates and underestimates 
include any difference of 0.1 mmHg or more from the 
reference device.
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statistically significant (Tables 4 and 5).
Further sensitivity analyses were conducted 
to check the influence of outliers (monitors 
with a very high mean difference compared 
with the others), as some monitors could 
have been faulty from the outset, but results 
were consistent with the main analyses.
All monitors passed the fast deflation 
test (deflation from 260 mmHg to 15 mmHg 
should take <10 seconds) and only one failed 
the air leakage check (inflating to between 
280–290 mmHg and requiring the pressure 
to drop less than 6 mmHg over 1 minute), but 
this device also failed the static pressure test. 
A total of 52 normal (22–30 cm), 45 large 
(30–42 cm), and 17 extra-large (42–48 cm) 
cuffs being used with the monitors were 
also assessed, all of which passed the fast 
deflation test and air leakage check.
DISCUSSION
Summary 
This study found that 13% of monitors that are 
used for BP checks in community pharmacies 
tested by the authors failed a standardised 
accuracy test, underestimating true BP, 
with the absolute pressure gap between the 
machines tested and the reference device 
increasing as BP rose. There was a trend for 
an increase in mean difference of monitors 
with longer service duration and higher 
usage but not to a statistically significant 
degree, perhaps due to lack of power. Failure 
rate of monitors after 18 months in use 
was significantly higher than for those with 
shorter service duration. Overall accuracy 
around the systolic diagnostic threshold of 
140 mmHg was good, with only small mean 
differences from reference.
Strengths and limitations 
This is the only study that the authors are 
aware of that considers the accuracy of 
monitors used in pharmacy BP checks, 
and one of the very few studies to assess 
accuracy of monitors with respect to time 
in service. As monitors in use were limited 
to two models, it provided an opportunity to 
consider calibration drift in the community 
for numbers of monitors not usually available 
on such a scale. 
The weaknesses of the data surrounding 
length of usage and service duration have 
been previously noted. Both under- and 
overestimation appeared dependent on 
who was asked. Length of time in service 
varied from 1 week to almost 3 years, which 
was surprising as the pharmacy chain in 
question has a policy of replacing the entire 
stock of monitors used for community 
testing every 2 years at the same time. The a 
priori intention in this study was to consider 
a cohort of monitors at the 18–24-month 
stage of the cycle, which in theory presented 
a rare opportunity for a reasonable sample 
size for this type of research. In reality 
there was an even spread of service 
duration. Furthermore, the chain’s policy of 
jettisoning all monitors at a predetermined 
point, including replacement monitors (that 
is, ones that may not have been in use for 
the full 2-year period), meant the sample 
size was relatively small, there being limited 
value in the study continuing further than it 
did, as all remaining monitors were about 
to be renewed.
Table 4. Monitor precision and failure rate by amount of usage, as 
reported by pharmacy staff
     
Category  Monitors Failure Mean difference, 
of usage Amount of usage tested, n rate, % (n) mmHg, (95%CI)
High Twice daily or more 12 17 (2) 1.05 (0.55 to 1.55)
Medium high More than once daily up to twice daily 10 20 (2) 0.68 (0.14 to 1.22)
Medium low More than four times weekly up to once daily 16 6 (1) 0.65 (0.23 to 1.07)
Low ‘Very little’ — up to four times weekly 17 6 (1) 0.67 (0.19 to 1.15)
Unsurea Undefined 6 33 (2) –
aUnsure refers to when staff were unable to provide evidence or estimate the amount of usage of a monitor.
Table 3. Monitor precision and failure rate by length of time in service
 Monitors Failure rate, Mean difference,  
Service duration, months tested, n % (n) mmHg (95% CI)
0–5 10 10 (1) 0.38 (–0.19 to 0.95)
6–12 17 0 (0) 0.74 (0.30 to 1.17)
13–18 11 9 (1) 0.72 (0.17 to 1.26)
19–24 9 33 (3) 1.09 (0.49 to 1.69)
>24 5 20 (1) 1.16 (0.35 to 1.96)
Unsurea 9 22 (2) –
aUnsure refers to when staff were unable to provide evidence or estimate the service duration of a monitor.
Table 5. Monitor precision and failure rate by amount of usage, head 
office data
     
Category Annual Pharmacies where Failure Mean difference, 
of usage usage rate monitors tested, n rate, % (n) mmHg (95% CI)
High 116–275.5 13 31 (4) 1.22 (0.72 to 1.71)
Medium high 86.5–108.5 10 10 (1) 0.87 (0.34 to 1.41)
Medium low 60.5–82.5 13 15 (2) 0.78 (0.32 to 1.24)
Low  13.5–59.5 16 6 (1) 0.47 (0.04 to 0.90)
Data available only at level of pharmacy (four failures happened in pharmacies where multiple devices were being 
used, making it difficult to interpret the relationship with usage). 
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As a consequence of the company’s 
2-year cycle, no formal calibration checking 
was carried out but several pharmacy 
staff anecdotally reported that they 
rejected any monitors they had concerns 
about (for example, where a monitor had 
been dropped or had liquids spilt on it, or 
alternatively if readings seemed spurious 
or likely to be wrong, albeit without formal 
testing against a reference device), sending 
them back to head office. This is reassuring 
and acts as a further level of quality control.
Comparison with existing literature
The failure rate of 13% identified in this study 
is very similar to that found by A’Court et al 29 
when testing monitors used in GP practices, 
namely 14% overall and 12% specifically for 
digital devices. Interestingly, for technical 
reasons those investigators were not able to 
test the monitors included in this study, which 
suggests that the underlying technologies 
in oscillometric monitors may be similarly 
robust. Of note, however, A’Court et al 
found no difference in accuracy by service 
duration over a 2-year period.29 Perhaps this 
discrepancy is due to differing usage rates: 
the estimates of usage from pharmacy staff 
correspond to the lower end of BP checks 
conducted in a typical GP surgery, where 
a BP machine would generally be used for 
many individuals per day.
In another study, 26% (12/47) of automated 
BP monitors in use at a hospital were 
not within 3 mmHg of a reference device, 
although only a minority of these machines 
were validated and it is unclear how long 
they had been in service.30 That study also 
found that calibration errors in automated 
devices tend to underestimate pressure. 
Conversely, 5% of automated BP monitors 
in GP practices failed but these devices were 
all provided by one manufacturer.31 There are 
very few studies that assess the accuracy of 
BP monitoring equipment over time. One 
study of 14 identical ambulatory monitors 
over a 6-year period found that 90% of a 
standardised set of pressure readings were 
within 2 mmHg on repeated measurement.32 
Implications for practice
Provision of BP monitoring facilities in 
community pharmacies has the potential 
to improve the quality of care for patients 
but depends on accurate monitors as well 
as robust communication systems with the 
rest of the health service. This work supports 
current recommendations for testing 
monitor accuracy annually but suggests that 
leaving monitors for as long as 2 years from 
purchase to testing may lead to potential for 
error. The main issues detected in this study 
were of underestimation of BP. Although 
pharmacists referred patients back to 
their GP rather than initiating treatment, 
reducing safety concerns associated with 
overdiagnosis, any underdiagnosis due to 
monitor underestimation of BP around 
clinical threshold levels represents a 
missed opportunity of pharmacy screening 
and management of hypertension, although 
most of the failures were at pressures higher 
than this. The effect could be exaggerated 
as previous research has highlighted 
community pharmacy-measured BP is 
lower than clinic-measured BP due to a 
reduced white-coat effect,33–35 even though 
a similar threshold for hypertension status 
is used by GPs and pharmacists. 
This research has implications for 
patients who self-monitor their BP, as 
these type of monitors retail on the high 
street and are very popular, because they 
are validated and inexpensive, selling up 
to millions of units.36 However, no advice is 
given (including in the manual provided) as to 
how long these monitors should be used for 
or how regularly they should be calibrated. 
Clearly, the amount of usage monitors will 
receive when purchased by one person 
for use in the home environment is less 
than those used regularly in pharmacy BP 
checks, but the accuracy of such monitors 
cannot be assumed indefinitely, especially 
as at least 30% of patients diagnosed with 
hypertension possess home BP measuring 
devices.37,38
Successive governments’ national policy 
has argued that expanding the range of 
services pharmacies provide will increase 
access and patient choice, reduce GP 
workload, and lower NHS costs.39,40 This 
work shows that one building block — 
namely monitor accuracy — can be safely 
put into place. However, the authors found 
large differences in the uptake of the BP 
checks in different pharmacies within 
the same chain, and this highlights the 
importance of implementation. More could 
be done to encourage people to use this 
service or to understand why some facilities 
are apparently more attractive than others. 
Community pharmacy BP checks 
present an excellent opportunity to improve 
hypertension diagnosis and management, 
but require accurate equipment. This study 
has shown BP monitors within this setting 
to be of similar accuracy to those in primary 
care, but that without similar calibration 
checks there is potential for error. These 
data indicate an annual calibration check 
is needed for this type of monitor, with 
evidence suggesting declining performance 
from 18 months onwards.
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